Indian Immunologicals Ltd (IIL), a subsidiary of National Dairy Development Board, will launch four new vaccines next year. The company is setting up a new manufacturing facility in Hyderabad with an investment of Rs 150 crore.
Announcing this in an official release, the company stated that it has plans to launch new vaccines for bovines, sheep and pets—Pentavalent vaccine for humans as well as vaccines for Japanese encephalitis, Brucellosis and Recombinant Tick vaccine in animals.
IIL is the largest veterinary vaccine manufacturer and exporter in the country and caters to nearly 80 per cent of foot and mouth (FMD) vaccine requirement. "Currently we have three manufacturing units, one in Ooty and two in Hyderabad. As per the plans the new facility in Hyderabad will be functional by mid next year. Built in an area of 50 acres the manufacturing unit will produce both human and animal vaccine. We are also in the process of launching a new improved vaccine against Brucellosis disease," said N. Anand, general manager-human health marketing, Indian Immunologicals.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
